<DOC>
	<DOCNO>NCT00729833</DOCNO>
	<brief_summary>The study conduct determine maximum tolerate dose , overall safety tolerability profile , pharmacokinetic profile CP-751,871 sunitinib give combination advance solid tumor .</brief_summary>
	<brief_title>Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study close enrollment 14 Jan 2011 terminate secondary excessive screen failure rate business reason associate Pfizer 's business decision stop development figitumumab compound . Safety concern contribute decision terminate clinical trial .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor relapse refractory standard therapy standard therapy exist . ECOG Performance Status 0 1 ; Total IGF1 level â‰¥100 ng/ml ; ECOG Performance Status 0 1 Adequate bone marrow , renal , hepatic function Concurrent treatment antitumor agent exception LHRH agnosits prostate cancer patient Treatment investigational therapy within 4 week prior study treatment Major surgery within 4 week study treatment Prior treatment may increase risk cardiac complication Ongoing cardiac dysrhythmias NCI CTCAE Grade 2 great Significant active cardiac disease , include hypertension control medication Greater three ( 3 ) prior line cytotoxic therapy ; Active infection Prior IGFIR target therapy ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>